These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 30643582)
1. Clinically relevant drug interactions with multikinase inhibitors: a review. Hussaarts KGAM; Veerman GDM; Jansman FGA; van Gelder T; Mathijssen RHJ; van Leeuwen RWF Ther Adv Med Oncol; 2019; 11():1758835918818347. PubMed ID: 30643582 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. Gay C; Toulet D; Le Corre P Hematol Oncol; 2017 Sep; 35(3):259-280. PubMed ID: 27925256 [TBL] [Abstract][Full Text] [Related]
3. Fluorescence-Based High-Throughput Assays for Investigating Cytochrome P450 Enzyme-Mediated Drug-Drug Interactions. He R; Dai Z; Finel M; Zhang F; Tu D; Yang L; Ge G Drug Metab Dispos; 2023 Oct; 51(10):1254-1272. PubMed ID: 37349113 [TBL] [Abstract][Full Text] [Related]
4. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Lee YC; Michael M; Zalcberg JR Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373 [TBL] [Abstract][Full Text] [Related]
5. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Houron C; Danielou M; Mir O; Fromenty B; Perlemuter G; Voican CS Crit Rev Oncol Hematol; 2021 Jan; 157():103127. PubMed ID: 33161366 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis. Zhu Y; Zhang X; Lou X; Chen M; Luo P; He Q Clin Exp Pharmacol Physiol; 2018 Jul; 45(7):659-667. PubMed ID: 29543385 [TBL] [Abstract][Full Text] [Related]
7. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Teo YL; Ho HK; Chan A Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025 [TBL] [Abstract][Full Text] [Related]
8. The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Gu R; Hibbs DE; Ong JA; Edwards RJ; Murray M Biochem Pharmacol; 2014 Mar; 88(2):245-52. PubMed ID: 24462920 [TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of human solute carrier transporters by multikinase inhibitors. Johnston RA; Rawling T; Chan T; Zhou F; Murray M Drug Metab Dispos; 2014 Nov; 42(11):1851-7. PubMed ID: 25165131 [TBL] [Abstract][Full Text] [Related]
10. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Xu ZY; Li JL Onco Targets Ther; 2019; 12():5467-5484. PubMed ID: 31371986 [TBL] [Abstract][Full Text] [Related]
11. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. Loulergue P; Merad M; Coriat R; Ducreux M; Planchard D; Boige V; Le Cesne A; Gregory TM; Poinsignon V; Paci A; Mir O Invest New Drugs; 2017 Apr; 35(2):247-249. PubMed ID: 27838867 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Blume H; Donath F; Warnke A; Schug BS Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963 [TBL] [Abstract][Full Text] [Related]
13. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294 [TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism. Akamine Y; Yasui-Furukori N; Uno T Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663 [TBL] [Abstract][Full Text] [Related]
15. A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions. Bogaard L; Tsoi K; van de Steeg B; Brandon EFA; Geers L; van Herwaarden M; Jansman F; Maas D; Monster-Simons M; Ong DSY; Borgsteede SD Front Pharmacol; 2024; 15():1412692. PubMed ID: 39403136 [TBL] [Abstract][Full Text] [Related]
16. Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Chanprapaph K; Rutnin S; Vachiramon V Am J Clin Dermatol; 2016 Aug; 17(4):387-402. PubMed ID: 27221667 [TBL] [Abstract][Full Text] [Related]
17. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters. Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Raoul JL; Edeline J; Simmet V; Moreau-Bachelard C; Gilabert M; Frénel JS Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267464 [TBL] [Abstract][Full Text] [Related]
19. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Hisaka A; Ohno Y; Yamamoto T; Suzuki H Pharmacol Ther; 2010 Feb; 125(2):230-48. PubMed ID: 19951720 [TBL] [Abstract][Full Text] [Related]
20. A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death. Xie Y; Li C; Huang Y; Jia Z; Cao J Oncotarget; 2017 Oct; 8(50):87209-87220. PubMed ID: 29152075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]